出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年5月
Biopharmaceutical Process Analytical Technology Market – Global Forecast to 2029
バイオ医薬品プロセス分析技術市場 : 技術（LC、GC、MS、qPCR、NGS、NMR、ラマン、赤外分光法）、製品（分析装置、センサー、ソフトウェア）、用途（ワクチン、生物製剤、CGT）、エンドユーザーの市場規模 – 2029年までの世界予測
Biopharmaceutical Process Analytical Technology Market Size by Technology (LC, GC, MS, qPCR, NGS, NMR, Raman, IR Spectroscopy), Product (Analyzer, Sensor, Software), Application (Vaccine, Biologics, CGT), and End User – Global Forecast to 2029
| ページ数 | 248 |
| 図表数 | 220 |
| 価格 | |
| シングルユーザライセンス | USD 4,950 |
| マルチユーザライセンス（5名） | USD 6,650 |
| コーポレートライセンス | USD 8,150 |
| エンタープライズサイトライセンス | USD 10,000 |
| 種別 | 英文調査報告書 |
Report Overview
The global biopharmaceutical process analytical technology market is projected to reach USD 2.6 billion by 2029 from USD 1.2 billion in 2024, at a CAGR of 16.0% during the forecast period of 2024 to 2029.
世界のバイオ医薬品プロセス分析技術市場は、2024年から2029年の予測期間中に16.0%のCAGRで、2024年の12億米ドルから2029年までに26億米ドルに達すると予測されています。
The market is on an upward trajectory fueled by a rise in biopharmaceutical research and development activities, coupled with technological advancements improving process efficiency. However, obstacles such as a shortage of skilled personnel and the high costs of implementing process analytical technology (PAT) are hindering the market’s growth.
“The liquid chromatography/HPLC segment to hold the largest share of the market in 2023.”
Based on the type, the global biopharmaceutical process analytical technology market has been classified into five major segments—liquid chromatography, gas chromatography, mass spectrometry, real-time PCR/QPCR, NGS, NMR spectroscopy, Raman spectroscopy, infrared spectroscopy, particle counters and imaging, differential light scattering, and other techniques. By technology, liquid chromatography/HPLC to hold major market share in 2023. The growing adoption of liquid chromatography/HPLC technologies for assessing the quality of biopharmaceutical drugs is a key driver behind the sector’s rapid expansion.
“The software segment is projected to register the highest CAGR during the forecast period.”
Biopharmaceutical process analytical technology (PAT) services are provided to enhance the implementation of the Quality by Design (QbD) framework. These services encompass various software solutions, including consultation on PAT adoption, software development, regulatory compliance, and process management. The software sector is expected to witness significant growth, driven by increasing demand for services essential in creating PAT models and executing PAT strategies in biopharmaceutical manufacturing.
“In terms of application, vaccines segment held the largest share of the market in 2023.”
Based on application, the biopharmaceutical process analytical technology market is broadly segmented into vaccines, cell and gene therapy, biosimilars & biologics, hormonal therapy, and other applications. The vaccines segment commanded the largest share of the market in 2023. Strict regulations in drug development and safety are the main drivers behind the expansion of this sector, bolstering the efficiency and effectiveness of biopharmaceutical manufacturing. Furthermore, heightened efforts in biopharmaceutical research and the expansion of production to address rising medicine demands are substantial contributors to this growth.
“The market in the APAC region is expected to witness the highest growth during the forecast period.”
China, India, and Japan are the key markets in the Asia Pacific. The growth of the Asia Pacific market is being driven by strategic expansions undertaken by major market players in emerging Asian nations, the flourishing Contract Research and Manufacturing Services (CRAMs) industry in India, Korea, Singapore, and China, the substantial biopharmaceutical industry presence in Singapore, as well as the organization of conferences, exhibitions, and meetings focusing on analytical instruments.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1 30%, Tier 2–42%, and Tier 3– 28%
• By Designation: C-level–14%, D Level–10%, and Others–76%
• By Region: North America–40%, Europe–30%, Asia Pacific–22%, Latin America–6%, and the Middle East & Africa–2%
The prominent players in the biopharmaceutical process analytical technology market are Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Shimadzu Corporation (Japan), Waters Corporation (US), Bruker Corporation (US), Emerson Electric Co. (US), ABB Ltd. (Switzerland), PerkinElmer, Inc. (US), Mettler-Toledo International Inc. (US), and Carl Zeiss AG (Germany), among others.
Research Coverage
This report studies the biopharmaceutical process analytical technology market based on type, product type, mode, application, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions)
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the biopharmaceutical process analytical technology market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the biopharmaceutical process analytical technology market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the biopharmaceutical process analytical technology market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
Table of Contents
1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS & EXCLUSIONS 31
1.3 MARKET SCOPE 32
1.3.1 MARKET SEGMENTATION 32
1.3.2 YEARS CONSIDERED 33
1.3.3 CURRENCY CONSIDERED 33
1.4 RESEARCH LIMITATIONS 33
1.5 STAKEHOLDERS 34
1.6 RECESSION IMPACT 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY RESEARCH 36
2.1.2 PRIMARY RESEARCH 36
2.1.2.1 Primary sources 37
2.1.2.2 Key industry insights 38
2.1.2.3 Breakdown of primaries 38
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 38
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.2 MARKET SIZE ESTIMATION 39
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 40
2.2.1 BOTTOM-UP APPROACH 40
2.2.1.1 Approach 1: Company revenue estimation approach 41
FIGURE 5 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION) 41
2.2.1.2 Approach 2: Customer-based market estimation 42
FIGURE 6 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 42
2.2.1.3 Growth forecast 43
2.2.1.4 CAGR projection 43
FIGURE 7 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS 43
2.3 DATA VALIDATION APPROACH 44
FIGURE 8 DATA TRIANGULATION METHODOLOGY 44
2.4 MARKET SHARE ASSESSMENT 45
2.5 STUDY ASSUMPTIONS 45
2.6 GROWTH RATE ASSUMPTIONS 45
2.7 RESEARCH LIMITATIONS 46
2.8 RISK ASSESSMENT 46
2.9 RECESSION IMPACT ANALYSIS 46
3 EXECUTIVE SUMMARY 47
FIGURE 9 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 47
FIGURE 10 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2024 VS. 2029 (USD MILLION) 48
FIGURE 11 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2024 VS. 2029 49
FIGURE 12 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: GEOGRAPHICAL SNAPSHOT 50
4 PREMIUM INSIGHTS 51
4.1 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET OVERVIEW 51
FIGURE 13 GROWING R&D EXPENDITURE BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH 51
4.2 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE 52
FIGURE 14 ONLINE MEASUREMENT TO DOMINATE MARKET DURING FORECAST PERIOD 52
4.3 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION AND APPLICATION 52
FIGURE 15 NORTH AMERICA TO HOLD LARGEST SHARE OF ALL APPLICATION SEGMENTS IN 2024 52
4.4 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 17 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.2.1 DRIVERS 55
5.2.1.1 Rising R&D investments by pharma companies and governments in emerging markets 55
FIGURE 18 PHARMACEUTICAL R&D EXPENDITURE: ANNUAL GROWTH RATE (%) 55
5.2.1.2 Growing incidence of infectious diseases and essential contribution of PAT in vaccine development 56
5.2.1.3 Requirement for improved efficiency in manufacturing processes driving enhancements in quality 56
5.2.1.4 Advancements in analytical device technology 57
5.2.2 RESTRAINTS 57
5.2.2.1 High cost of process analytical technology deployment 57
5.2.2.2 Governmental regulations pertaining to safety of drugs 57
5.2.3 OPPORTUNITIES 58
5.2.3.1 Increasing interest in PAT in emerging markets 58
5.2.3.2 Increasing utilization of analytical instruments in biopharmaceutical processes 59
5.2.4 CHALLENGES 60
5.2.4.1 Lack of skilled professionals 60
5.3 REGULATORY ANALYSIS 61
5.3.1 REGULATORY LANDSCAPE 61
TABLE 1 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PROCESS ANALYTICAL TECHNOLOGY, BY COUNTRY/REGION 61
5.3.2 KEY REGULATORY BODIES & GOVERNMENT AGENCIES 61
TABLE 2 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
TABLE 3 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 4 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 5 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 6 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
5.3.3 KEY REGULATORY GUIDELINES 64
5.3.3.1 US 64
5.3.3.2 Europe 64
5.3.3.3 Asia Pacific 65
5.3.3.4 Rest of the World 65
5.4 VALUE CHAIN ANALYSIS 65
FIGURE 19 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: VALUE CHAIN ANALYSIS 66
5.5 SUPPLY CHAIN ANALYSIS 66
5.5.1 PROMINENT COMPANIES 66
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES 66
5.5.3 END USERS 66
FIGURE 20 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: SUPPLY CHAIN ANALYSIS 67
5.6 ECOSYSTEM ANALYSIS 67
FIGURE 21 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: ECOSYSTEM ANALYSIS 67
TABLE 7 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: ROLE IN ECOSYSTEM 68
5.7 INVESTMENT & FUNDING SCENARIO 68
FIGURE 22 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022 68
FIGURE 23 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022 (USD MILLION) 69
5.8 PRICING ANALYSIS 69
FIGURE 24 AVERAGE SELLING PRICE TREND OF MAJOR PROCESS ANALYTICAL TECHNOLOGIES, BY TYPE (USD THOUSAND) 70
FIGURE 25 AVERAGE SELLING PRICE TREND OF MAJOR PROCESS ANALYTICAL TECHNOLOGIES, BY REGION (USD THOUSAND) 70
TABLE 8 AVERAGE SELLING PRICE OF PROCESS ANALYTICAL TECHNOLOGIES, BY REGION, 2021–2023 (USD THOUSAND) 71
5.9 TRADE ANALYSIS 72
5.9.1 IMPORT DATA 72
TABLE 9 IMPORT DATA FOR CHROMATOGRAPHY SYSTEMS (HS CODE 902720), BY COUNTRY, 2019–2023 (USD THOUSAND) 72
TABLE 10 IMPORT DATA FOR SPECTROMETERS, SPECTROPHOTOMETERS, AND SPECTROGRAPHS (HS CODE 902730), BY COUNTRY, 2019–2023 (USD THOUSAND) 72
5.9.2 EXPORT DATA 73
TABLE 11 EXPORT DATA FOR CHROMATOGRAPHY SYSTEMS (HS CODE 902720), BY COUNTRY, 2019–2023 (USD THOUSAND) 73
TABLE 12 EXPORT DATA FOR SPECTROMETERS, SPECTROPHOTOMETERS, AND SPECTROGRAPHS (HS CODE 902730), BY COUNTRY, 2019–2023 (USD THOUSAND) 73
5.10 PATENT ANALYSIS 74
5.10.1 PATENT DETAILS FOR BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY (JANUARY 2013–DECEMBER 2023) 74
5.11 PORTER’S FIVE FORCE ANALYSIS 75
TABLE 13 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 75
5.11.1 THREAT OF NEW ENTRANTS 75
5.11.2 THREAT OF SUBSTITUTES 75
5.11.3 BARGAINING POWER OF SUPPLIERS 75
5.11.4 BARGAINING POWER OF BUYERS 75
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 76
5.12 KEY CONFERENCES & EVENTS 76
TABLE 14 LIST OF MAJOR CONFERENCES & EVENTS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET IN JANUARY 2024-DECEMBER 2024 76
5.13 CASE STUDY ANALYSIS 77
5.13.1 NAVIGATING DIGITAL TRANSFORMATION: INTEGRATING ADVANCED TECHNOLOGIES FOR PAT IN BIOPHARMACEUTICAL MANUFACTURING. 77
5.13.1.1 Case 1: Advancements in process analytical technology 77
5.14 TECHNOLOGY ANALYSIS 77
5.14.1 KEY TECHNOLOGIES 77
5.14.1.1 Mass spectrometry (MS) 77
5.14.1.2 Liquid chromatography/HPLC 78
5.14.2 COMPLEMENTARY TECHNOLOGIES 78
5.14.2.1 Advanced sensor technologies 78
5.14.3 ADJACENT TECHNOLOGIES 79
5.14.3.1 Bioprocess monitoring and control systems 79
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79
FIGURE 26 REVENUE SHIFT IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET 79
5.16 KEY STAKEHOLDERS & BUYING CRITERIA 80
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 80
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES 80
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%) 80
5.16.2 BUYING CRITERIA 81
FIGURE 28 KEY BUYING CRITERIA FOR PROCESS ANALYTICAL TECHNOLOGY 81
TABLE 16 KEY BUYING CRITERIA FOR PROCESS ANALYTICAL TECHNOLOGY 81
5.17 UNMET NEEDS AND KEY PAIN POINTS 82
TABLE 17 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: CURRENT UNMET NEEDS 82
6 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY TYPE 83
6.1 INTRODUCTION 84
TABLE 18 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 84
TABLE 19 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET VOLUME, BY TYPE, 2022–2029 (MILLION UNITS) 85
TABLE 20 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION) 85
6.2 LIQUID CHROMATOGRAPHY/HPLC 86
6.2.1 EARLY AND EFFICIENT SAMPLE ANALYSIS ASSOCIATED WITH LC TO DRIVE MARKET GROWTH 86
TABLE 21 DIFFERENTIATION OF LIQUID CHROMATOGRAPHY SYSTEMS 86
TABLE 22 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY REGION, 2022–2029 (USD MILLION) 87
TABLE 23 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY MODE, 2022–2029 (USD MILLION) 87
TABLE 24 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY APPLICATION, 2022–2029 (USD MILLION) 88
6.3 GAS CHROMATOGRAPHY 88
6.3.1 GROWING ADOPTION OF COMPACT GC SYSTEMS IN MANUFACTURING FACILITIES TO BOLSTER GROWTH 88
TABLE 25 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY REGION, 2022–2029 (USD MILLION) 89
TABLE 26 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY MODE, 2022–2029 (USD MILLION) 89
TABLE 27 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY APPLICATION, 2022–2029 (USD MILLION) 90
6.4 MASS SPECTROMETRY 90
6.4.1 GROWING NEED FOR DUAL-MASS ANALYZERS TO PROPEL GROWTH 90
TABLE 28 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION) 91
TABLE 29 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY MODE, 2022–2029 (USD MILLION) 91
TABLE 30 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY APPLICATION, 2022–2029 (USD MILLION) 92
6.5 REAL-TIME PCR/QPCR 92
6.5.1 EXPANSION OF PCR INSTRUMENTATION TO FAVOR MARKET GROWTH 92
TABLE 31 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY REGION, 2022–2029 (USD MILLION) 93
TABLE 32 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY MODE, 2022–2029 (USD MILLION) 93
TABLE 33 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY APPLICATION, 2022–2029 (USD MILLION) 94
6.6 NEXT-GENERATION SEQUENCING 94
6.6.1 INCREASING INVESTMENTS IN NEXT-GENERATION SEQUENCING (NGS) TECHNOLOGIES TO DRIVE MARKET EXPANSION 94
TABLE 34 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION) 95
TABLE 35 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY MODE, 2022–2029 (USD MILLION) 95
TABLE 36 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY APPLICATION, 2022–2029 (USD MILLION) 96
6.7 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 96
6.7.1 ADVANCING BIOPHARMACEUTICAL QUALITY AND EFFICIENCY THROUGH NMR SPECTROSCOPY TO BOOST MARKET 96
TABLE 37 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION) 97
TABLE 38 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION) 97
TABLE 39 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION) 98
6.8 RAMAN SPECTROSCOPY 98
6.8.1 EXPANDING ROLE OF RAMAN SPECTROSCOPY IN PROCESS MONITORING AND QUALITY CONTROL TO BOOST MARKET 98
TABLE 40 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION) 99
TABLE 41 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION) 99
TABLE 42 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION) 100
6.9 INFRARED SPECTROSCOPY 100
6.9.1 INCREASING UTILIZATION OF MINIATURIZED GC SYSTEMS IN PRODUCTION PLANTS TO SUPPORT GROWTH 100
TABLE 43 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION) 101
TABLE 44 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION) 101
TABLE 45 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION) 102
6.10 PARTICLE COUNTERS & IMAGING 102
6.10.1 INCREASING DEMAND FOR HIGH-QUALITY MEDICATIONS WITH REDUCED SIDE EFFECTS TO FACILITATE MARKET ACCEPTANCE 102
TABLE 46 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY REGION, 2022–2029 (USD MILLION) 103
TABLE 47 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY MODE, 2022–2029 (USD MILLION) 103
TABLE 48 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY APPLICATION, 2022–2029 (USD MILLION) 104
6.11 DIFFERENTIAL LIGHT SCATTERING 104
6.11.1 CONTROLLED MANUFACTURING OF PHARMACEUTICALS WITH FEWER SIDE EFFECTS TO BOOST ADOPTION 104
TABLE 49 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY REGION, 2022–2029 (USD MILLION) 105
TABLE 50 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY MODE, 2022–2029 (USD MILLION) 105
TABLE 51 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY APPLICATION, 2022–2029 (USD MILLION) 106
6.12 OTHER TECHNIQUES 106
TABLE 52 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY REGION, 2022–2029 (USD MILLION) 107
TABLE 53 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY MODE, 2022–2029 (USD MILLION) 107
TABLE 54 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY APPLICATION, 2022–2029 (USD MILLION) 108
7 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY PRODUCT TYPE 109
7.1 INTRODUCTION 110
TABLE 55 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 110
7.2 ANALYZERS 110
7.2.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH 110
TABLE 56 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR ANALYZERS, BY REGION, 2022–2029 (USD MILLION) 111
7.3 SENSORS & PROBES 112
7.3.1 QUICK TURNAROUND TIMES AND AUTOMATED PROCESSES TO FACILITATE MARKET ADOPTION 112
TABLE 57 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SENSORS & PROBES, BY REGION, 2022–2029 (USD MILLION) 112
7.4 SAMPLERS 113
7.4.1 HIGH LEVEL OF ACCURACY AND REPRODUCIBILITY TO DRIVE MARKET GROWTH 113
TABLE 58 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SAMPLERS, BY REGION, 2022–2029 (USD MILLION) 113
7.5 SOFTWARE 114
7.5.1 GROWING ADOPTION OF PAT FRAMEWORKS WITHIN PHARMACEUTICAL COMPANIES TO BOLSTER ADOPTION 114
TABLE 59 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SOFTWARE, BY REGION, 2022–2029 (USD MILLION) 115
8 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY MODE 116
8.1 INTRODUCTION 117
TABLE 60 COMPARISON BETWEEN MEASUREMENT METHODS IN PAT 117
TABLE 61 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION) 117
8.2 ONLINE MEASUREMENT 118
8.2.1 IMPROVED PROCESS EFFICIENCY AND REDUCED PRODUCTION COSTS TO BOOST ADOPTION 118
TABLE 62 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR ONLINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION) 118
8.3 OFFLINE MEASUREMENT 119
8.3.1 HIGH FLEXIBILITY OF OFFLINE ANALYSIS TO DRIVE GROWTH 119
TABLE 63 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OFFLINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION) 119
8.4 AT-LINE MEASUREMENT 120
8.4.1 GROWING USE OF AT-LINE MEASUREMENT TO BOOST MARKET GROWTH 120
TABLE 64 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR AT-LINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION) 120
8.5 IN-LINE MEASUREMENT 121
8.5.1 FAST TURNAROUND TIME TO BOOST SEGMENTAL GROWTH 121
TABLE 65 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR IN-LINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION) 121
9 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY APPLICATION 122
9.1 INTRODUCTION 123
TABLE 66 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 123
9.2 VACCINES 123
9.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH FOR VACCINES 123
TABLE 67 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR VACCINES, BY REGION, 2022–2029 (USD MILLION) 124
9.3 CELL & GENE THERAPY 125
9.3.1 GROWING DEMAND FOR STEM CELL AND CAR-T THERAPIES TO BOOST MARKET GROWTH 125
TABLE 68 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR CELL & GENE THERAPY, BY REGION, 2022–2029 (USD MILLION) 126
9.4 BIOSIMILARS & BIOLOGICS 126
9.4.1 HIGH LEVELS OF ACCURACY AND REPRODUCIBILITY TO PROPEL DEMAND FOR BIOSIMILARS & BIOLOGICS 126
TABLE 69 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR BIOSIMILARS & BIOLOGICS, BY REGION, 2022–2029 (USD MILLION) 127
9.5 HORMONAL THERAPY 127
9.5.1 IMPROVING CANCER TREATMENT WITH ADVANCED HORMONAL THERAPY TO FAVOR MARKET GROWTH 127
FIGURE 29 GLOBAL CANCER CASES, 202O VS. 2022 128
TABLE 70 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR HORMONAL THERAPY, BY REGION, 2022–2029 (USD MILLION) 128
9.6 OTHER APPLICATIONS 129
TABLE 71 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 129
10 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY REGION 130
10.1 INTRODUCTION 131
TABLE 72 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION) 131
10.2 NORTH AMERICA 131
FIGURE 30 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SNAPSHOT 132
10.2.1 NORTH AMERICA: RECESSION IMPACT 133
TABLE 73 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 74 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 134
TABLE 75 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION) 134
TABLE 76 NORTH AMERICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 135
TABLE 77 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 135
10.2.2 US 135
10.2.2.1 Stringent regulations and dominance of pharma and biopharma firms to propel market growth 135
TABLE 78 US: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 136
10.2.3 CANADA 137
10.2.3.1 Widespread occurrence of cancer and promising funding landscape to bolster market growth 137
TABLE 79 CANADA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 138
10.3 EUROPE 138
10.3.1 EUROPE: RECESSION IMPACT 139
TABLE 80 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 81 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 140
TABLE 82 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION) 140
TABLE 83 EUROPE: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 141
TABLE 84 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 141
10.3.2 GERMANY 141
10.3.2.1 Growing adoption of biopharmaceutical process analytical technology (PAT) to propel market 141
TABLE 85 GERMANY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 142
10.3.3 FRANCE 143
10.3.3.1 Infrastructure development and increasing life science R&D investment to propel growth 143
TABLE 86 FRANCE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 143
10.3.4 UK 144
10.3.4.1 Government initiatives to boost market expansion 144
TABLE 87 UK: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 145
10.3.5 ITALY 145
10.3.5.1 Conducive funding environment in Italy to boost market 145
TABLE 88 ITALY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 146
10.3.6 SPAIN 146
10.3.6.1 Growing focus on cancer screening and digital health initiatives to boost market 146
TABLE 89 SPAIN: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 147
10.3.7 REST OF EUROPE 147
TABLE 90 REST OF EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 148
10.4 ASIA PACIFIC 148
FIGURE 31 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SNAPSHOT 149
10.4.1 ASIA PACIFIC: RECESSION IMPACT 150
TABLE 91 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 92 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 151
TABLE 93 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION) 151
TABLE 94 ASIA PACIFIC: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 152
TABLE 95 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 152
10.4.2 JAPAN 152
10.4.2.1 Advanced infrastructure to support market growth in Japan 152
TABLE 96 JAPAN: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 153
10.4.3 CHINA 153
10.4.3.1 Growing demand for PAT to boost market 153
TABLE 97 CHINA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 154
10.4.4 INDIA 155
10.4.4.1 Growing biopharmaceutical industry to drive market growth 155
TABLE 98 INDIA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 155
10.4.5 AUSTRALIA 156
10.4.5.1 Government investments to propel market growth 156
TABLE 99 AUSTRALIA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 157
10.4.6 SOUTH KOREA 157
10.4.6.1 Extensive insurance coverage to boost market growth 157
TABLE 100 SOUTH KOREA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 158
10.4.7 REST OF ASIA PACIFIC 158
TABLE 101 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 159
10.5 LATIN AMERICA 159
10.5.1 LATIN AMERICA: RECESSION IMPACT 159
TABLE 102 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 103 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 160
TABLE 104 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION) 161
TABLE 105 LATIN AMERICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 161
TABLE 106 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 162
10.5.2 BRAZIL 162
10.5.2.1 Expansion within biopharmaceutical sector to contribute to market growth 162
TABLE 107 BRAZIL: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 163
10.5.3 MEXICO 163
10.5.3.1 Growing exports of biopharmaceuticals to drive market in Mexico 163
TABLE 108 MEXICO: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 164
10.5.4 REST OF LATIN AMERICA 164
TABLE 109 REST OF LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 165
10.6 MIDDLE EAST & AFRICA 165
10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 166
TABLE 110 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 111 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION) 167
TABLE 112 MIDDLE EAST & AFRICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 168
TABLE 113 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 168
11 COMPETITIVE LANDSCAPE 169
11.1 OVERVIEW 169
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 169
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET 170
TABLE 114 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURING COMPANIES 170
11.3 REVENUE ANALYSIS 171
FIGURE 32 REVENUE ANALYSIS OF TOP THREE PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET (2019–2023) 171
11.4 MARKET SHARE ANALYSIS 172
FIGURE 33 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 172
TABLE 115 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DEGREE OF COMPETITION 172
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 173
11.5.1 STARS 174
11.5.2 EMERGING LEADERS 174
11.5.3 PERVASIVE PLAYERS 174
11.5.4 PARTICIPANTS 174
FIGURE 34 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 175
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS 176
FIGURE 35 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY FOOTPRINT 176
TABLE 116 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PRODUCT FOOTPRINT 177
TABLE 117 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: REGIONAL FOOTPRINT 178
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES 179
11.6.1 PROGRESSIVE COMPANIES 179
11.6.2 RESPONSIVE COMPANIES 179
11.6.3 DYNAMIC COMPANIES 179
11.6.4 STARTING BLOCKS 179
FIGURE 36 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 180
11.6.5 COMPETITIVE BENCHMARKING 181
TABLE 118 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 181
TABLE 119 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 182
11.7 COMPANY VALUATION & FINANCIAL METRICS 183
FIGURE 37 EV/EBITDA OF KEY VENDORS 183
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 183
11.8 BRAND/PRODUCT COMPARISON 184
FIGURE 39 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL 184
11.9 COMPETITIVE SCENARIO 185
11.9.1 PRODUCT LAUNCHES 185
TABLE 120 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024 185
11.9.2 DEALS 186
TABLE 121 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DEALS, JANUARY 2020–MARCH 2024 186
11.9.3 EXPANSIONS 190
TABLE 122 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: EXPANSIONS, JANUARY 2020–APRIL 2024 190
12 COMPANY PROFILES 191
12.1 KEY PLAYERS 191
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 WATERS CORPORATION 191
TABLE 123 WATERS CORPORATION: COMPANY OVERVIEW 191
FIGURE 40 WATERS CORPORATION: COMPANY SNAPSHOT (2023) 192
TABLE 124 WATERS CORPORATION: PRODUCTS OFFERED 192
TABLE 125 WATERS CORPORATION: DEALS 193
12.1.2 DANAHER CORPORATION 194
TABLE 126 DANAHER CORPORATION: COMPANY OVERVIEW 194
FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2023) 195
TABLE 127 DANAHER CORPORATION: PRODUCTS OFFERED 195
TABLE 128 DANAHER CORPORATION: DEALS 196
12.1.3 THERMO FISHER SCIENTIFIC INC. 197
TABLE 129 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 197
FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 198
TABLE 130 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 198
TABLE 131 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES 199
TABLE 132 THERMO FISHER SCIENTIFIC INC.: DEALS 200
12.1.4 AGILENT TECHNOLOGIES, INC. 202
TABLE 133 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 202
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 203
TABLE 134 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 203
TABLE 135 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES 204
TABLE 136 AGILENT TECHNOLOGIES, INC.: DEALS 204
12.1.5 SHIMADZU CORPORATION 206
TABLE 137 SHIMADZU CORPORATION: COMPANY OVERVIEW 206
FIGURE 44 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2022) 207
TABLE 138 SHIMADZU CORPORATION: PRODUCTS OFFERED 208
TABLE 139 SHIMADZU CORPORATION: PRODUCT LAUNCHES 209
TABLE 140 SHIMADZU CORPORATION: EXPANSIONS 210
12.1.6 PERKINELMER, INC. 211
TABLE 141 PERKINELMER, INC.: COMPANY OVERVIEW 211
FIGURE 45 PERKINELMER, INC.: COMPANY SNAPSHOT (2022) 212
TABLE 142 PERKINELMER, INC.: PRODUCTS OFFERED 213
TABLE 143 PERKINELMER, INC.: PRODUCT LAUNCHES 213
12.1.7 BRUKER CORPORATION 214
TABLE 144 BRUKER CORPORATION: COMPANY OVERVIEW 214
FIGURE 46 BRUKER CORPORATION: COMPANY SNAPSHOT (2023) 215
TABLE 145 BRUKER CORPORATION: PRODUCTS OFFERED 216
TABLE 146 BRUKER CORPORATION: PRODUCT LAUNCHES 217
TABLE 147 BRUKER CORPORATION: DEALS 218
12.1.8 METTLER-TOLEDO INTERNATIONAL INC. 219
TABLE 148 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY OVERVIEW 219
FIGURE 47 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY SNAPSHOT (2023) 220
TABLE 149 METTLER-TOLEDO INTERNATIONAL INC.: PRODUCTS OFFERED 220
TABLE 150 METTLER-TOLEDO INTERNATIONAL INC.: DEALS 222
12.1.9 CARL ZEISS AG (ZEISS GROUP) 223
TABLE 151 CARL ZEISS AG: COMPANY OVERVIEW 223
FIGURE 48 CARL ZEISS AG: COMPANY SNAPSHOT (2022) 224
TABLE 152 CARL ZEISS AG: PRODUCTS OFFERED 224
12.1.10 EMERSON ELECTRIC CO. 225
TABLE 153 EMERSON ELECTRIC CO.: COMPANY OVERVIEW 225
FIGURE 49 EMERSON ELECTRIC CO.: COMPANY OVERVIEW 226
TABLE 154 EMERSON ELECTRIC CO.: PRODUCTS OFFERED 226
12.1.11 ABB 227
TABLE 155 ABB: COMPANY OVERVIEW 227
FIGURE 50 ABB: COMPANY SNAPSHOT (2023) 228
TABLE 156 ABB: PRODUCTS OFFERED 228
TABLE 157 ABB: EXPANSIONS 229
12.1.12 SARTORIUS AG 230
TABLE 158 SARTORIUS AG: COMPANY OVERVIEW 230
FIGURE 51 SARTORIUS AG: COMPANY SNAPSHOT (2023) 231
TABLE 159 SARTORIUS AG: PRODUCTS OFFERED 231
TABLE 160 SARTORIUS AG: DEALS 232
TABLE 161 SARTORIUS AG: EXPANSIONS 232
12.1.13 PROCESS INSIGHTS, INC. 233
TABLE 162 PROCESS INSIGHTS, INC.: COMPANY OVERVIEW 233
TABLE 163 PROCESS INSIGHTS, INC.: PRODUCTS OFFERED 233
12.1.14 MERCK KGAA 234
TABLE 164 MERCK KGAA: COMPANY OVERVIEW 234
FIGURE 52 MERCK KGAA: COMPANY SNAPSHOT (2023) 235
TABLE 165 MERCK KGAA: PRODUCTS OFFERED 236
TABLE 166 MERCK KGAA: DEALS 236
12.1.15 VERUM ANALYTICS, LLC 238
TABLE 167 VERUM ANALYTICS, LLC: COMPANY OVERVIEW 238
TABLE 168 VERUM ANALYTICS, LLC: PRODUCTS OFFERED 239
12.2 OTHER PLAYERS 240
12.2.1 HAMILTON COMPANY 240
12.2.2 ENDRESS+HAUSER GROUP SERVICES AG 241
12.2.3 VIAVI SOLUTIONS INC. 241
12.2.4 METROHM AG 242
12.2.5 CONTROL DEVELOPMENT, INC. 243
12.2.6 NECI 243
12.2.7 SCHMIDT + HAENSCH 244
12.2.8 SENSUM D.O.O. 245
12.2.9 AMETEK, INC. 246
12.2.10 SENTRONIC GMBH 247
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 248
13.1 DISCUSSION GUIDE 248
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 252
13.3 CUSTOMIZATION OPTIONS 254
13.4 RELATED REPORTS 254
13.5 AUTHOR DETAILS 255